Menu Our services in the selected location:
  • No services available for your region.
Select Location:
Remember my selection
Your browser is out of date.

Alternatives

LIFE SCIENCES

Goldman Sachs Life Sciences seeks to invest in the next generation of leading biotech, pharma, and diagnostics companies.

Video

Our Life Sciences Strategy


Learn why we believe the life sciences industry represents one of the most attractive growth segments today.

 

Amit Sinha

CIO of Goldman Sachs Life Sciences

Amit Sinha

 

“We are in a golden era of innovation in life sciences, where discoveries are rapidly translated into life changing medicines.” 

 

Goldman Sachs Life Sciences

What Makes Us Different?

 

Our domain expertise, deep network, and advisory capabilities position us to identify the most promising therapeutics companies, manage risk prudently and maximize value creation.

 

Sourcing

We operate a robust, multi-channel sourcing engine that leverages Goldman Sachs’ relationships across academic and medical institutions, corporates, venture capital and private equity firms, and company founders and executives. 

 

Capital Formation

We believe that many life sciences companies would benefit from scaling privately, but a funding gap has historically forced these companies to go public too early. By better aligning investment capital with company innovation, we hope to drive better outcomes for companies and, ultimately, patients.

 

Value Creation

We partner with companies to enhance and accelerate value creation by helping them establish the right business and financial strategies, execute, and achieve strong exits.

About Our Team

Our team is comprised of experienced life sciences investors with deep domain expertise across disciplines.

Leadership Team

 

Amit Sinha

CIO of Goldman Sachs Life Sciences

Amit is CIO and Global Head of Life Sciences investing based in San Francisco. Joined Goldman Sachs in 2004.

Amit Sinha

 


 

Amit is CIO and Global Head of Life Sciences Investing. Amit has 21 years of experience in the life sciences sector and was former Global Head of Biotechnology Investment Banking at Goldman Sachs. Amit has a B.S. in Biology from Stanford and an MBA from Harvard Business School. 

Josh Richardson, M.D.

Managing Director & Senior Investor

Josh Richardson, M.D.

 


 

Josh is a Managing Director and senior investor on the Life Sciences Investing Team. Josh has 14 years of experience including life sciences VC and public markets investing. Prior to joining Goldman Sachs, Josh was a Managing Director at Longitude Capital. Josh has a B.S. in Biomedical Science from University of South Florida and M.D. from University of Virginia.

Kevin Xu

Managing Director & Senior Investor

Kevin Xu

 


 

Kevin is a Managing Director and senior investor on the Life Sciences Investing Team, based in Hong Kong. Kevin has 15 years of experience in China healthcare and private equity investing and was previously at Basso Capital Management. Kevin has a B.S. in Finance from University of Maryland and MBA from University of Cambridge.

Advisory Board

Our investment team is complemented by an industry leading Advisory Board comprised of academics, clinicians, scientific experts, and entrepreneurs.

 

David Chang, M.D., Ph.D.

CEO, Allogene

David Chang, M.D., Ph.D.

 


 

David is the former CMO of Kite Pharma. He has extensive hematology-oncology experience in industry and academics at Amgen, Dana-Farber and UCLA. David has a B.S. in Biology from M.I.T. and a M.D. / Ph.D. from Stanford University.

Ross Levine, M.D.

Deputy Physician-in-Chief and Translational Research, Memorial Sloan Kettering

Ross Levine, M.D.

 


 

Ross is an Attending Physician on the Leukemia Service, Department of Medicine and a Professor of Medicine at Weill Cornell Medical College. Ross has prior clinical training and experience in internal medicine and hematology-oncology at Massachusetts General and Dana-Farber. Ross has an A.B. from Harvard College and M.D. from Johns Hopkins.

Lloyd Minor, M.D.

Dean, Stanford University School of Medicine

Lloyd Minor, M.D.

 


 

Lloyd is former Provost of Johns Hopkins University & Chair of the department of Otolaryngology. He is a  Member of the National Academy of Medicine. Lloyd has a Sc.B. / M.D. from Brown University.

Sean Nolan

Biotech Executive

Sean Nolan

 


 

Sean is the former CEO of Avexis. He has extensive executive operating experience, including CBO Intermune and senior roles with Lundbeck/Ovation and Reata. Sean has a B.S. in Biology from John Carroll University.

Innovation Themes

Goldman Sachs Life Sciences focuses on six themes.

Precision Medicine

Precision medicine is the ability to deliver medicines that target a patient’s underlying cause of disease based on their genetics or other unique biological characteristics.

Genetic Medicine

Genetic medicine is the ability to alter a patient’s gene expression to treat disease through the introduction or alteration of genetic material.

Cell Therapy

Cell therapy is the ability to use specific, genetically-engineered cells to combat disease or regenerate tissue.

Artificial Intelligence/Machine Learning

Machine learning is the ability to use advanced computation to understand complex biology and design potential therapeutics.

Immunotherapy

Immunotherapy is the ability to engage and manipulate the immune system as an approach to treating disease.

Synthetic Biology

Synthetic biology is the redesign of living systems for useful purposes, including medicines.

As of September 1, 2022. This information discusses general market activity, industry or sector trends, or other broad-based economic, market or political conditions and should not be construed as research or investment advice. This material has been prepared by Goldman Sachs and is not financial research nor a product of Goldman Sachs Global Investment Research (GIR). It was not prepared in compliance with applicable provisions of law designed to promote the independence of financial analysis and is not subject to a prohibition on trading following the distribution of financial research. The views and opinions expressed may differ from those of Goldman Sachs Global Investment Research or other departments or divisions of Goldman Sachs and its affiliates. Investors are urged to consult with their financial advisors before buying or selling any securities. This information may not be current and Goldman Sachs has no obligation to provide any updates or changes.

Featured Investments

 

Precision Medicine

Moma Therapeutics: Biopharmaceutical company focused on discovering the next generation of precision medicines by targeting molecular machines that underlie human disease.

 

Precision Medicine

Nested Therapeutics: Biotechnology company focused on discovering and developing small molecule precision medicines by targeting cancer-associated mutations that have historically been challenging to drug.

Featured Investments were selected to highlight the most recent investment as of October 1, 2022. A full list of assets is available upon request. For illustrative purposes only. Performance results vary depending on the client’s investment goals, objectives, and constraints. There can be no assurance that the same or similar results to those presented above can or will be achieved.

Resources

GSAM Perspectives | Sept. 2, 2022

Life Sciences: Entering a Golden Era of Innovation


Exchanges at GS | Aug. 16, 2022

Why We're In a 'Golden Age' of Life Sciences Innovation


Talks at GS | May 16, 2022

Ryan Watts, CEO and Co-Founder of Denali Therapeutics


Exchanges at GS | March 23, 2022

Gene Editing: The Future of Genomic Medicine & Biotech Investing


Exchanges at GS | March 2, 2021

How Healthcare CIOs Are Investing Capital Through a Public Health Crisis


May 20, 2021

Vaccines, Recovery and Innovation in the Healthcare Sector


Ready to learn more about our life sciences capabilities?

 

Please reach out to your Goldman Sachs Asset Management relationship manager.

Disclosures

Alternative Investments - Hedge funds and other private investment funds (collectively, “Alternative Investments”) are subject to less regulation than other types of pooled investment vehicles such as mutual funds. Alternative Investments may impose significant fees, including incentive fees that are based upon a percentage of the realized and unrealized gains and an individual’s net returns may differ significantly from actual returns. Such fees may offset all or a significant portion of such Alternative Investment’s trading profits. Alternative Investments are not required to provide periodic pricing or valuation information. Investors may have limited rights with respect to their investments, including limited voting rights and participation in the management of such Alternative Investments. 

Alternative Investments often engage in leverage and other investment practices that are extremely speculative and involve a high degree of risk. Such practices may increase the volatility of performance and the risk of investment loss, including the loss of the entire amount that is invested. There may be conflicts of interest relating to the Alternative Investment and its service providers, including Goldman Sachs and its affiliates. Similarly, interests in an Alternative Investment are highly illiquid and generally are not transferable without the consent of the sponsor, and applicable securities and tax laws will limit transfers. 

 

Conflicts of Interest

There may be conflicts of interest relating to the Alternative Investment and its service providers, including Goldman Sachs and its affiliates. These activities and interests include potential multiple advisory, transactional and other interests in securities and instruments that may be purchased or sold by the Alternative Investment. These are considerations of which investors should be aware and additional information relating to these conflicts is set forth in the offering materials for the Alternative Investment.

A fund, underlying funds, and/or portfolio assets may utilize leverage which could have significant adverse consequences. In particular, a fund will lose its investment in a leveraged portfolio investment more quickly than a non-leveraged portfolio investment if the portfolio investment declines in value. Money borrowed for the purpose of leveraging investments will also be subject to interest costs as well as financing, transaction and other fees and costs that may not be recovered. You should understand fully the risks associated with the use of leverage before making an investment in a fund. 

This information discusses general market activity, industry or sector trends, or other broad-based economic, market or political conditions and should not be construed as research or investment advice. This material is not financial research nor a product of Goldman Sachs Global Investment Research (GIR). It was not prepared in compliance with applicable provisions of law designed to promote the independence of financial analysis and is not subject to a prohibition on trading following the distribution of financial research. The views and opinions expressed may differ from those of Goldman Sachs Global Investment Research or other departments or divisions of Goldman Sachs and its affiliates. Investors are urged to consult with their financial advisors before buying or selling any securities. This information may not be current and Goldman Sachs has no obligation to provide any updates or changes. 

This material represents the views of Goldman Sachs Asset Management. It is not financial research or a product of Goldman Sachs Global Investment Research (GIR). It was not a product nor financial research of Goldman Sachs Global Investment Research (GIR). It was not prepared in compliance with applicable provisions of law designed to promote the independence of financial analysis and is not subject to a prohibition on trading following the distribution of financial research. The views and opinions expressed herein may vary significantly from those expressed by GIR or any other groups at Goldman Sachs. Investors are urged to consult with their financial advisers before buying or selling any securities. The information contained herein should not be relied upon in making an investment decision or be construed as investment advice. Goldman Sachs Asset Management has no obligation to provide any updates or changes.

Company names and logos, excluding those of Goldman Sachs and any of its affiliates, are trademarks or registered trademarks of their respective holders. Use by Goldman Sachs does not imply or suggest a sponsorship, endorsement or affiliation.

THIS MATERIAL DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL TO DO SO. 

Prospective investors should inform themselves as to any applicable legal requirements and taxation and exchange control regulations in the countries of their citizenship, residence or domicile which might be relevant.

This material is provided for informational purposes only and should not be construed as investment advice or an offer or solicitation to buy or sell securities. This material is not intended to be used as a general guide to investing, or as a source of any specific investment recommendations, and makes no implied or express recommendations concerning the manner in which any client’s account should or would be handled, as appropriate investment strategies depend upon the client’s investment objectives.

Although certain information has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness. We have relied upon and assumed without independent verification, the accuracy and completeness of all information available from public sources.

Views and opinions expressed are for informational purposes only and do not constitute a recommendation by Goldman Sachs Asset Management to buy, sell, or hold any security. Views and opinions are current as of the date of this presentation and may be subject to change, they should not be construed as investment advice.

Entities Providing Services. This presentation is intended only to facilitate your discussions with the applicable Goldman Sachs entity including, but not limited to, Goldman Sachs & Co. LLC, Goldman Sachs International, Goldman Sachs AG, Goldman Sachs Paris Inc. Et Cie., Goldman Sachs Saudi Arabia, Goldman Sachs Bank AG, Goldman Sachs (Asia) L.L.C, Goldman Sachs (Singapore) Pte (Company Number: 19862165W), Goldman Sachs Futures Pte. Ltd (Company Number: 199004153Z); Goldman Sachs Australia Pty Limited. In connection with its distribution in the United Kingdom, this material has been issued and approved by Goldman Sachs International which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and Prudential Regulation Authority. This material has been approved for issue in the United Kingdom solely for the purposes of Section 21 of the Financial Services and Markets Act 2000 by GSI, Plumtree Court, 25 Shoe Lane, London EC4A 4AU; by Goldman Sachs Canada, in connection with its distribution in Canada; in the United States by Goldman Sachs & Co. LLC; in Hong Street (Beijing) Equity Investment Management Co., Ltd., in Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in Japan by Goldman Sachs Japan Co., Ltd; in Australia by Goldman Sachs Australia Pty Ltd (ACN 006 797 897); and in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 19862165W). 

This material represents the views of Goldman Sachs Asset Management. It is not financial research or a product of Goldman Sachs Global Investment Research (GIR). It was not a product nor financial research of Goldman Sachs Global Investment Research (GIR). It was not prepared in compliance with applicable provisions of law designed to promote the independence of financial analysis and is not subject to a prohibition on trading following the distribution of financial research. The views and opinions expressed herein may vary significantly from those expressed by GIR or any other groups at Goldman Sachs. Investors are urged to consult with their financial advisers before buying or selling any securities. The information contained herein should not be relied upon in making an investment decision or be construed as investment advice. Goldman Sachs Asset Management has no obligation to provide any updates or changes. 

Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold or directly invest in the company or its securities. Nothing in this document should be construed to constitute allocation advice or recommendations. 

United Kingdom and European Economic Area (EEA): In the United Kingdom, this material is a financial promotion and has been approved by Goldman Sachs Asset Management International, which is authorized and regulated in the United Kingdom by the Financial Conduct Authority. 

Switzerland: This is marketing material. 

EU: This material is a financial promotion disseminated by Goldman Sachs Bank Europe SE, including through its authorised branches ("GSBE"). GSBE is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism established between those Member States of the European Union whose official currency is the Euro, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufischt, BaFin) and Deutsche Bundesbank.

Outside EU: In the United Kingdom, this material is a financial promotion and has been approved by Goldman Sachs International, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority.

Qatar: This document has not been, and will not be, registered with or reviewed or approved by the Qatar Financial Markets Authority, the Qatar Financial Centre Regulatory Authority or Qatar Central Bank and may not be publicly distributed. It is not for general circulation in the State of Qatar and may not be reproduced or used for any other purpose.

Saudi Arabia: The Capital Market Authority does not make any representation as to the accuracy or completeness of this document, and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. If you do not understand the contents of this document you should consult an authorised financial adviser.

Australia: This material is distributed by Goldman Sachs Asset Management Australia Pty Ltd ABN 41 006 099 681, AFSL 228948 (‘GSAMA’) and is intended for viewing only by wholesale clients for the purposes of section 761G of the Corporations Act 2001 (Cth).  This document may not be distributed to retail clients in Australia (as that term is defined in the Corporations Act 2001 (Cth)) or to the general public. This document may not be reproduced or distributed to any person without the prior consent of GSAMA.

To the extent that this document contains any statement which may be considered to be financial product advice in Australia under the Corporations Act 2001 (Cth), that advice is intended to be given to the intended recipient of this document only, being a wholesale client for the purposes of the Corporations Act 2001 (Cth). Any advice provided in this document is provided by either Goldman Sachs Asset Management International (GSAMI), Goldman Sachs International (GSI), Goldman Sachs Asset Management, LP (GSAMLP) or Goldman Sachs & Co. LLC (GSCo). Both GSCo and GSAMLP are regulated by the US Securities and Exchange Commission under US laws, which differ from Australian laws. Both GSI and GSAMI are regulated by the Financial Conduct Authority and GSI is authorized by the Prudential Regulation Authority under UK laws, which differ from Australian laws. GSI, GSAMI, GSCo, and GSAMLP are all exempt from the requirement to hold an Australian financial services licence under the Corporations Act of Australia and therefore do not hold any Australian Financial Services Licences. Any financial services given to any person by GSI, GSAMI, GSCo or GSAMLP by distributing this document in Australia are provided to such persons pursuant to ASIC Class Orders 03/1099 and 03/1100.

No offer to acquire any interest in a fund or a financial product is being made to you in this document.  If the interests or financial products do become available in the future, the offer may be arranged by GSAMA in accordance with section 911A(2)(b) of the Corporations Act.  GSAMA holds Australian Financial Services Licence No. 228948.  Any offer will only be made in circumstances where disclosure is not required under Part 6D.2 of the Corporations Act or a product disclosure statement is not required to be given under Part 7.9 of the Corporations Act (as relevant).

FOR DISTRIBUTION ONLY TO FINANCIAL INSTITUTIONS, FINANCIAL SERVICES LICENSEES AND THEIR ADVISERS. NOT FOR VIEWING BY RETAIL CLIENTS OR MEMBERS OF THE GENERAL PUBLIC.

Hong Kong: The distribution of this material and the placement of interests in the fund(s) mentioned in Hong Kong is restricted.  Accordingly, unless permitted by the securities laws of Hong Kong, no person may issue or have in its possession for the purposes of issue, this material, or any advertisement, invitation or document relating to the interests in the fund(s) mentioned, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong, other than with respect to the interests in the fund(s) mentioned which are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) and any rules made thereunder.

This material has been issued or approved for use in or from Hong Kong by Goldman Sachs Asset Management (Hong Kong) Limited. 

Singapore: This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may shares  be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i) to an institutional investor specified  in  section 304 of the Securities and Futures Act, Chapter 289 of Singapore (“SFA”) or (ii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

This material has been issued or approved for use in or from Singapore by Goldman Sachs Asset Management (Singapore) Pte. Ltd. (Company Number: 201329851H).

280435-OTU-1629761

 

Please enter your email address to continue reading.

Confirm Your Access


An email has been sent to you to verify ownership of your email address.

Please verify the link in the email by clicking the confirmation button. Once completed, you will gain instant access to our insights.

If you did not receive the email from us please check your spam folder or try again.